Not yet taking people in Finnország2. fázis
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?
Key facts
- Where
- Turku, FinnországSee the site
- Phase
- 2. fázis
Where in Finnország
- Turku University HospitalTurku, FinnországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- EU 2024-511104-16-00
- Record updated
- 2024. február 28.
- Original description
Evaluate the lesion-specific expression of prostate-specific membrane antigen (PSMA) and fibroblast activation-protein (FAP) in metastatic prostate cancerRead full original descriptionShow less
Evaluate the lesion-specific expression of prostate-specific membrane antigen (PSMA) and fibroblast activation-protein (FAP) in metastatic prostate cancer
Inclusion: Men with histologically confirmed prostate cancer; Age 50-85 years at baseline; WHO performance score 0-2; At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single-photon emission computed tomography (SPECT) imaging; All previous treatment lines are allowed; Patient signs informed consent form after receiving written information.
Exclusion: Medical conditions prohibiting whole-body PET/CT imaging; Patient is not able to understand the purpose of the study.